Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.37 Bil Enterprise Value: 13.42 Bil PE Ratio: 71.45 PB Ratio: 2.86 GF Score: 62/100

Biomarin Pharmaceutical Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 09, 2021 / 07:25PM GMT
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Hello, everyone. My name is Gena Wang, and I'm the midcap biotech Analyst at the Barclays. Welcome to our second virtual global healthcare conference. And first, I wish everyone stay healthy, and I would like to thank all the participants, investors, companies and especially our events team and corporate access team, who made this virtual healthcare conference possible.

With that, I would like to introduce our next presenting company, BioMarin. With us, we have J.J. Bienaimé, Chairman and Chief Executive Officer; Hank Fuchs, President, Worldwide Research and Development; Brian Mueller, Chief Financial Officer.

With that, I will hand over to you, J.J. to give opening remarks.

Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO

Thank you, Gena, and thank you for all of us for joining us on today's call. So last week, we announced strong results in the fourth quarter and the full year 2020, demonstrating our continued operational

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot